HC Wainwright Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $25.00

Keros Therapeutics (NASDAQ:KROS) had its price objective decreased by HC Wainwright from $40.00 to $25.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 82.72% from the company’s current price.

A number of other research analysts also recently issued reports on the company. Piper Sandler reduced their price objective on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research note on Friday, January 17th. Cantor Fitzgerald downgraded Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 21st. Wedbush restated a “neutral” rating and issued a $15.00 target price on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Truist Financial cut their price target on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, April 9th. Finally, Scotiabank lowered their price objective on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research note on Thursday, January 16th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.67.

Keros Therapeutics Price Performance

KROS opened at $13.68 on Thursday. Keros Therapeutics has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The firm has a market capitalization of $555.64 million, a P/E ratio of -2.63 and a beta of 1.32. The company’s 50-day moving average is $12.10 and its 200 day moving average is $25.34.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping the consensus estimate of ($0.01) by $3.63. The firm had revenue of $211.25 million for the quarter, compared to analysts’ expectations of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same quarter last year, the firm earned ($1.21) EPS. On average, equities research analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current year.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the company’s stock in a transaction that occurred on Wednesday, April 9th. The stock was bought at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the purchase, the insider now owns 4,392,737 shares of the company’s stock, valued at approximately $44,498,425.81. This represents a 27.01 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 22.90% of the stock is owned by corporate insiders.

Institutional Trading of Keros Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Federated Hermes Inc. increased its position in shares of Keros Therapeutics by 882.3% in the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company’s stock worth $12,474,000 after purchasing an additional 1,099,519 shares during the last quarter. Corton Capital Inc. bought a new stake in Keros Therapeutics during the first quarter worth about $186,000. CWM LLC increased its position in shares of Keros Therapeutics by 10,157.7% during the 1st quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after purchasing an additional 2,641 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Keros Therapeutics during the 1st quarter valued at about $25,000. Finally, Rhumbline Advisers lifted its position in Keros Therapeutics by 9.3% in the 1st quarter. Rhumbline Advisers now owns 44,669 shares of the company’s stock worth $455,000 after buying an additional 3,802 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.